1. Prolonged survival in patients with resected non–small cell lung cancer and single-level N2 disease 
Steven M Keller, MD, Mark G Vangel, PhD, Henry Wagner, MD, Joan H Schiller, MD, Arnold Herskovic, MD, Ritsuko Komaki, MD, Randolph S Marks, MD, Michael C Perry, MD, Robert B Livingston, MD, David H Johnson, MD 
The Journal of Thoracic and Cardiovascular Surgery 
Volume 128, Issue 1, Pages (July 2004)
DOI: /j.jtcvs

2. Figure 1
Median survival was 65.4 months (95% CI, months) for patients with N1 disease and 30.6 months (95% CI, months) for all patients with N2 disease; 5-year survivals were 52% and 32%, respectively.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs )

3. Figure 2
Median survival was 51.4 months (95% CI, 22.3 months–not reached) for patients with left upper lobe tumors and single-level N2 metastases and 49.4 months (95% CI, months) for patients with left upper lobe tumors and N1 disease; 5-year survival was 42% in both groups.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs )

4. Figure 3
Median survival was 20 months (95% CI, months) for patients with multi-level N2 disease and 35.3 months (95% CI, months) for patients with single-level N2 disease.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs )

5. Figure 4
Median survival was 51.4 months (95% CI, 22.3 months–not reached) for patients with left upper lobe tumors and single-level N2 metastases and 18.2 months (95% CI, 7.6 months–not reached) for patients with multiple-level N2 disease. The difference approximated statistical significance.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs )

6. Figure 5
Median survival was 58.8 months (95% CI, months) for patients with solitary N2 skip metastases compared with 25.6 months (95% CI, months) for patients with concomitant N1 and N2 disease; 5-year survivals were 50% and 18%, respectively.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs )